Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephanie Lheureux

Showing results (81-90 of 134) with videos related to

Pageof 14
Sort By:
Proceedings of the National Academy of Sciences of the United States of America|June 23, 2021
Computational modeling of ovarian cancer dynamics suggests optimal strategies for therapy and screeningShengqing Gu, Stephanie Lheureux, Azin Sayad, et al.
Cancer Research Communications|March 26, 2026
Pre-Clinical Combination Targeting VEGF and PI3K in a Rare, Aggressive Mixed Endometrial Carcinoma: An Applied Case ReportNikolina Radulovich, Pamela Soberanis Pina, Molly L Udaskin, et al.
Journal of Gynecologic Oncology|December 22, 2024
Phase II randomized study of dostarlimab alone or with bevacizumab versus non-platinum chemotherapy in recurrent gynecological clear cell carcinoma (DOVE/APGOT-OV7/ENGOT-ov80)Jung-Yun Lee, David Tan, Isabelle Ray-Coquard, et al.
Nature Communications|May 13, 2026
Maveropepimut-S, pembrolizumab and low dose cyclophosphamide in metastatic ovarian cancer: phase 1/2 PESCO trialAna C Veneziani, Stephanie Lheureux, Douglas G Millar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 4, 2025
Novel Systemic Anticancer Treatments and Health Services Use at the End of Life Among Adults With CancerJavaid Iqbal, Rahim Moineddin, Kieran L Quinn, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|January 20, 2019
<i>TP53</i> mutations in high grade serous ovarian cancer and impact on clinical outcomes: a comparison of next generation sequencing and bioinformatics analysesVictoria Mandilaras, Swati Garg, Michael Cabanero, et al.
Nature Reviews. Cancer|May 12, 2019
Going to extremes: determinants of extraordinary response and survival in patients with cancerFlurina A M Saner, Alan Herschtal, Brad H Nelson, et al.
Obstetrics and Gynecology International|June 12, 2018
Malignant Bowel Obstruction in Advanced Gynecologic Cancers: An Updated Review from a Multidisciplinary PerspectiveYeh Chen Lee, Nazlin Jivraj, Catherine O'Brien, et al.
Cell Reports|August 28, 2025
T cell receptor repertoire in cell-free DNA as a proxy for tumor infiltrates in patients treated with pembrolizumabShirin Soleimani, Xuan Li, Ben X Wang, et al.
Translational Oncology|August 24, 2025
Elucidating divergent biology in uterine carcinosarcomaVikas Garg, Stephenie D Prokopec, Simone C Stone, et al.
Pageof 14

Showing results (81-90 of 134) with videos related to

Sort By:
Pageof 14
Proceedings of the National Academy of Sciences of the United States of America|June 23, 2021
Computational modeling of ovarian cancer dynamics suggests optimal strategies for therapy and screeningShengqing Gu, Stephanie Lheureux, Azin Sayad, et al.
Cancer Research Communications|March 26, 2026
Pre-Clinical Combination Targeting VEGF and PI3K in a Rare, Aggressive Mixed Endometrial Carcinoma: An Applied Case ReportNikolina Radulovich, Pamela Soberanis Pina, Molly L Udaskin, et al.
Journal of Gynecologic Oncology|December 22, 2024
Phase II randomized study of dostarlimab alone or with bevacizumab versus non-platinum chemotherapy in recurrent gynecological clear cell carcinoma (DOVE/APGOT-OV7/ENGOT-ov80)Jung-Yun Lee, David Tan, Isabelle Ray-Coquard, et al.
Nature Communications|May 13, 2026
Maveropepimut-S, pembrolizumab and low dose cyclophosphamide in metastatic ovarian cancer: phase 1/2 PESCO trialAna C Veneziani, Stephanie Lheureux, Douglas G Millar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 4, 2025
Novel Systemic Anticancer Treatments and Health Services Use at the End of Life Among Adults With CancerJavaid Iqbal, Rahim Moineddin, Kieran L Quinn, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|January 20, 2019
<i>TP53</i> mutations in high grade serous ovarian cancer and impact on clinical outcomes: a comparison of next generation sequencing and bioinformatics analysesVictoria Mandilaras, Swati Garg, Michael Cabanero, et al.
Nature Reviews. Cancer|May 12, 2019
Going to extremes: determinants of extraordinary response and survival in patients with cancerFlurina A M Saner, Alan Herschtal, Brad H Nelson, et al.
Obstetrics and Gynecology International|June 12, 2018
Malignant Bowel Obstruction in Advanced Gynecologic Cancers: An Updated Review from a Multidisciplinary PerspectiveYeh Chen Lee, Nazlin Jivraj, Catherine O'Brien, et al.
Cell Reports|August 28, 2025
T cell receptor repertoire in cell-free DNA as a proxy for tumor infiltrates in patients treated with pembrolizumabShirin Soleimani, Xuan Li, Ben X Wang, et al.
Translational Oncology|August 24, 2025
Elucidating divergent biology in uterine carcinosarcomaVikas Garg, Stephenie D Prokopec, Simone C Stone, et al.
Pageof 14